BlackRock Fund Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

BlackRock Fund Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$78K	Buy	555 +223	+67%	+$24.6K	﹤0.01%	3668
2016 Q3	$34K	Sell	332 -1	-0.3%	-$81	﹤0.01%	3836
2016 Q2	$24K	Sell	333 -3,301	-91%	-$309K	﹤0.01%	3892
2016 Q1	$335K	Buy	+3,634	New	+$322K	﹤0.01%	3309

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $3.85B AUM 13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Family Management New York $834M AUM 20.83% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

BlackRock Fund Advisors's IMDX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Insight Molecular Diagnostics (IMDX) stake by 67% in Q4 2016, buying an estimated $24.6K and bringing the position to 555 shares worth $78K. The position accounts for ﹤0.01% of the portfolio, ranked #3668.

BlackRock Fund Advisors first reported a position in IMDX in Q1 2016 and has held it in 4 quarters since. The position peaked at $335K in Q1 2016. 32 funds tracked by Wall St. Rank hold IMDX as of Q4 2016.

BlackRock Fund Advisors held 555 shares of Insight Molecular Diagnostics worth $78K as of Q4 2016.
BlackRock Fund Advisors bought 223 Insight Molecular Diagnostics shares in Q4 2016, an estimated $24.6K.
Insight Molecular Diagnostics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3668 holding.
BlackRock Fund Advisors first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 4 quarters since.
BlackRock Fund Advisors's Insight Molecular Diagnostics position peaked at $335K in Q1 2016.
32 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.